Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in pat... Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. Mehr anzeigen
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights PR Newswire AUSTIN, Texas, Nov. 14, 2024 Announced promising safety and positive biomarker data...
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) PR Newswire WALTHAM, Mass., Nov. 13, 2024...
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma PR Newswire AUSTIN, Texas and NEW YORK, Oct. 31, 2024...
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium...
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) PR Newswire AUSTIN, Texas, Sept. 23, 2024...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.89 | -23.670212766 | 3.76 | 4 | 2.84 | 91106 | 3.55682037 | CS |
| 4 | -0.67 | -18.9265536723 | 3.54 | 4.4 | 2.84 | 94773 | 3.77596625 | CS |
| 12 | 0.44 | 18.1069958848 | 2.43 | 4.4 | 2.2 | 76491 | 3.41535508 | CS |
| 26 | -1.13 | -28.25 | 4 | 4.4 | 1.61 | 70837 | 3.15241239 | CS |
| 52 | 1.28 | 80.5031446541 | 1.59 | 7.42 | 1.52 | 85085 | 3.92670379 | CS |
| 156 | -14.63 | -83.6 | 17.5 | 17.63802 | 1.01 | 239488 | 6.17630911 | CS |
| 260 | -7.53 | -72.4038461538 | 10.4 | 49.4 | 1.01 | 593493 | 23.24983088 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
